Literature DB >> 18539308

Relationship of HIV-1 and SIV envelope glycoprotein trimer occupation and neutralization.

Emma T Crooks1, Pengfei Jiang, Michael Franti, Sharon Wong, Michael B Zwick, James A Hoxie, James E Robinson, Penny L Moore, James M Binley.   

Abstract

Insights into the process of HIV-1 neutralization may assist rational vaccine design. Here, we compared antibody neutralization against the JR-FL primary isolate and trimer binding affinities judged by native PAGE. Monovalent Fab-trimer binding and neutralization showed a direct quantitative relationship, implying that neutralization begins as each trimer is occupied by one antibody. At saturation, three Fab or soluble CD4 molecules engaged each trimer. In contrast, a maximum of one soluble CD4 molecule bound to functional SIV trimers with a truncated a gp41 tail. Remarkably, soluble CD4 was found to trigger dramatic enhancement of this virus. Unlike Fabs, a quantitative correlation between JR-FL trimer binding and neutralization was unclear for some, but not all IgGs, as neutralization was markedly increased, but trimer affinity was largely unchanged. In addition, only one molecule of certain gp41-specific IgGs appeared to be able to bind each trimer. We discuss the implications of these findings in weighing the relative contributions of size, multivalent binding and other possible effects of IgGs to explain their increased potency.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18539308      PMCID: PMC2516379          DOI: 10.1016/j.virol.2008.04.045

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  88 in total

1.  Biochemical and biological characterization of a dodecameric CD4-Ig fusion protein: implications for therapeutic and vaccine strategies.

Authors:  James Arthos; Claudia Cicala; Tavis D Steenbeke; Tae-Wook Chun; Charles Dela Cruz; Douglas B Hanback; Prateeti Khazanie; Daniel Nam; Peter Schuck; Sara M Selig; Donald Van Ryk; Margery A Chaikin; Anthony S Fauci
Journal:  J Biol Chem       Date:  2002-01-22       Impact factor: 5.157

2.  Solid-phase proteoliposomes containing human immunodeficiency virus envelope glycoproteins.

Authors:  Christoph Grundner; Tajib Mirzabekov; Joseph Sodroski; Richard Wyatt
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

3.  Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design.

Authors:  E O Saphire; P W Parren; R Pantophlet; M B Zwick; G M Morris; P M Rudd; R A Dwek; R L Stanfield; D R Burton; I A Wilson
Journal:  Science       Date:  2001-08-10       Impact factor: 47.728

4.  Characterization of neutralization epitopes of simian immunodeficiency virus (SIV) recognized by rhesus monoclonal antibodies derived from monkeys infected with an attenuated SIV strain.

Authors:  K S Cole; M Alvarez; D H Elliott; H Lam; E Martin; T Chau; K Micken; J L Rowles; J E Clements; M Murphey-Corb; R C Montelaro; J E Robinson
Journal:  Virology       Date:  2001-11-10       Impact factor: 3.616

5.  The stoichiometry of trimeric SIV glycoprotein interaction with CD4 differs from that of anti-envelope antibody Fab fragments.

Authors:  M Kim; B Chen; R E Hussey; Y Chishti; D Montefiori; J A Hoxie; O Byron; G Campbell; S C Harrison; E L Reinherz
Journal:  J Biol Chem       Date:  2001-09-05       Impact factor: 5.157

6.  CD4 independence of simian immunodeficiency virus Envs is associated with macrophage tropism, neutralization sensitivity, and attenuated pathogenicity.

Authors:  Bridget A Puffer; Stefan Pöhlmann; Aimee L Edinger; Dan Carlin; Melissa D Sanchez; Julie Reitter; Debbie D Watry; Howard S Fox; Ronald C Desrosiers; Robert W Doms
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

7.  Purification and characterization of oligomeric envelope glycoprotein from a primary R5 subtype B human immunodeficiency virus.

Authors:  Indresh K Srivastava; Leonidas Stamatatos; Harold Legg; Elaine Kan; Anne Fong; Stephen R Coates; Louisa Leung; Mark Wininger; John J Donnelly; Jeffrey B Ulmer; Susan W Barnett
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

8.  Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41.

Authors:  M B Zwick; A F Labrijn; M Wang; C Spenlehauer; E O Saphire; J M Binley; J P Moore; G Stiegler; H Katinger; D R Burton; P W Parren
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

9.  Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody.

Authors:  D R Burton; J Pyati; R Koduri; S J Sharp; G B Thornton; P W Parren; L S Sawyer; R M Hendry; N Dunlop; P L Nara
Journal:  Science       Date:  1994-11-11       Impact factor: 47.728

10.  Cryptic nature of envelope V3 region epitopes protects primary monocytotropic human immunodeficiency virus type 1 from antibody neutralization.

Authors:  D C Bou-Habib; G Roderiquez; T Oravecz; P W Berman; P Lusso; M A Norcross
Journal:  J Virol       Date:  1994-09       Impact factor: 5.103

View more
  37 in total

1.  Three-dimensional structures of soluble CD4-bound states of trimeric simian immunodeficiency virus envelope glycoproteins determined by using cryo-electron tomography.

Authors:  Tommi A White; Alberto Bartesaghi; Mario J Borgnia; M Jason V de la Cruz; Rachna Nandwani; James A Hoxie; Julian W Bess; Jeffrey D Lifson; Jacqueline L S Milne; Sriram Subramaniam
Journal:  J Virol       Date:  2011-09-21       Impact factor: 5.103

2.  HIV type 1 Env precursor cleavage state affects recognition by both neutralizing and nonneutralizing gp41 antibodies.

Authors:  Bimal K Chakrabarti; Marie Pancera; Sanjay Phogat; Sijy O'Dell; Krisha McKee; Javier Guenaga; James Robinson; John Mascola; Richard T Wyatt
Journal:  AIDS Res Hum Retroviruses       Date:  2011-01-19       Impact factor: 2.205

3.  HIV-1 virus-like particles bearing pure env trimers expose neutralizing epitopes but occlude nonneutralizing epitopes.

Authors:  Tommy Tong; Ema T Crooks; Keiko Osawa; James M Binley
Journal:  J Virol       Date:  2012-02-01       Impact factor: 5.103

4.  Role of complex carbohydrates in human immunodeficiency virus type 1 infection and resistance to antibody neutralization.

Authors:  James M Binley; Yih-En Andrew Ban; Emma T Crooks; Dirk Eggink; Keiko Osawa; William R Schief; Rogier W Sanders
Journal:  J Virol       Date:  2010-03-24       Impact factor: 5.103

5.  Structural and immunogenicity studies of a cleaved, stabilized envelope trimer derived from subtype A HIV-1.

Authors:  Yun Kenneth Kang; Sofija Andjelic; James M Binley; Emma T Crooks; Michael Franti; Sai Prasad N Iyer; Gerald P Donovan; Antu K Dey; Ping Zhu; Kenneth H Roux; Robert J Durso; Thomas F Parsons; Paul J Maddon; John P Moore; William C Olson
Journal:  Vaccine       Date:  2009-06-28       Impact factor: 3.641

6.  Intra-spike crosslinking overcomes antibody evasion by HIV-1.

Authors:  Rachel P Galimidi; Joshua S Klein; Maria S Politzer; Shiyu Bai; Michael S Seaman; Michel C Nussenzweig; Anthony P West; Pamela J Bjorkman
Journal:  Cell       Date:  2015-01-29       Impact factor: 41.582

7.  Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C.

Authors:  James M Binley; Elizabeth A Lybarger; Emma T Crooks; Michael S Seaman; Elin Gray; Katie L Davis; Julie M Decker; Diane Wycuff; Linda Harris; Natalie Hawkins; Blake Wood; Cory Nathe; Douglas Richman; Georgia D Tomaras; Frederic Bibollet-Ruche; James E Robinson; Lynn Morris; George M Shaw; David C Montefiori; John R Mascola
Journal:  J Virol       Date:  2008-09-24       Impact factor: 5.103

8.  In-solution virus capture assay helps deconstruct heterogeneous antibody recognition of human immunodeficiency virus type 1.

Authors:  Daniel P Leaman; Heather Kinkead; Michael B Zwick
Journal:  J Virol       Date:  2010-01-20       Impact factor: 5.103

9.  A conformational switch in human immunodeficiency virus gp41 revealed by the structures of overlapping epitopes recognized by neutralizing antibodies.

Authors:  Robert Pejchal; Johannes S Gach; Florence M Brunel; Rosa M Cardoso; Robyn L Stanfield; Philip E Dawson; Dennis R Burton; Michael B Zwick; Ian A Wilson
Journal:  J Virol       Date:  2009-06-10       Impact factor: 5.103

10.  Few and far between: how HIV may be evading antibody avidity.

Authors:  Joshua S Klein; Pamela J Bjorkman
Journal:  PLoS Pathog       Date:  2010-05-27       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.